60 Degrees Pharma Ahead of Schedule on Babesiosis Trial Enrollment
SXTP is trading near its 52-week low of $1.29 (12% above the low).
Summary
60 Degrees Pharmaceuticals announced the early enrollment of the first patient in its clinical trial for tafenoquine to treat babesiosis, putting the company approximately one month ahead of schedule. This positive clinical progress follows recent disclosures of a critical 4-month cash runway and substantial doubt about the company's ability to continue as a going concern, as reported in their March 30th 10-K and May 15th 10-Q filings. The company previously reported highly positive results from an expanded use trial for relapsing babesiosis on March 11th. For a micro-cap company facing severe financial distress, being ahead of schedule on a clinical trial for a potentially life-saving drug is a significant positive development. It could be crucial for attracting necessary financing and improving investor sentiment. The company expects to achieve minimum enrollment as soon as early July, with interim analysis dates to be announced approximately 50 days after enrollment completion.
At the time of this announcement, SXTP was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $1.29 to $14.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.